multiple sclerosis

Showing 15 posts of 105 posts found.

Sanofi announce positive phase 2 data for MS drug frexalimab

June 1, 2023
Research and Development Neurology, Sanofi, clinical trial, frexalimab, multiple sclerosis

French pharmaceutical and healthcare company Sanofi have announced positive trial data from its phase 2 clinical study into its relapsing …


Biogen announces collaboration on novel MS treatment

July 13, 2021
Manufacturing and Production multiple sclerosis

Biogen and InnoCare Pharma have announced a license and collaboration agreement for orelabrutinib, an oral small molecule Bruton’s tyrosine kinase …

Novartis multiple sclerosis treatment recommended by NICE

April 20, 2021
Manufacturing and Production NICE, Novartis, multiple sclerosis, pharma, pharma news

NICE have recommenced Novartis’ ofatumumab (Kesimpta) for the treatment of relapsing remitting MS (RRMS) in adult patients for use on …

Janssen’s multiple sclerosis treatment recommended by EMA

March 29, 2021
Sales and Marketing CHMP, EMA, Janssen, Johnson & Johnson, PONVORY, multiple sclerosis

Janssen’s PONVORY therapy for the treatment of adults with relapsing forms of multiple sclerosis (MS) has been recommended by the …


NHS England increases access to cladribine tablets for multiple sclerosis patients during pandemic

March 3, 2021
Research and Development Cladribine, Mavenclad, Merck, multiple sclerosis

NHS England has updated the Blueteq requirements for patients with highly active relapsing MS starting Merck’s cladribine (Mavenclad) tablets during …


CHMP recommends marketing authorisation for Novartis’ Kesimpta

February 1, 2021
Sales and Marketing Novartis, multiple sclerosis

The EMA’s Committee for Medicinal Products for Human Use (CHMP) has recommended the marketing authorisation of Novartis’ Kesimpta (ofatumumab) for …


Biogen’s IM Plegridy gets EU approval

January 6, 2021
Research and Development Biogen, multiple sclerosis

The European Commission has approved Biogen’s Plegridy (peginterferon beta-1a), a new intramuscular (IM) injection for the treatment of relapsing-remitting multiple …


Biogen agrees to pay $22m to settle kickback allegations

December 18, 2020
Medical Communications Biogen, multiple sclerosis

Biogen has agreed to pay $22 million to put an end to an investigation into claims that it illegally used …


FDA greenlights Glenmark’s generic version of Biogen’s Tecfidera in relapsing multiple sclerosis

October 7, 2020
Research and Development, Sales and Marketing Biogen, Glenmark, generic, multiple sclerosis

Glenmark Pharma will be celebrating after it secured FDA approval in the US to market dimethyl fumarate, a generic version …


BMS’ Zeposia becomes first S1P receptor modulator available in Europe for relapsing remitting multiple sclerosis

May 28, 2020
Sales and Marketing Avonex, Bristol-Myers Squibb, EU, Europe, Zeposia, bristol myers squibb, multiple sclerosis

Bristol Myers Squibb is celebrating after its oral therapy Zeposia (ozanimod), secured European Commission for the treatment of relapsing remitting …


FDA approves BMS’ Zeposia in relapsing multiple sclerosis, but COVID-19 will delay its market entry

March 26, 2020
Sales and Marketing Bristol-Myers Squibb, COVID-19, Zeposia, coronavirus, multiple sclerosis, pharma

Bristol-Myers Squibb has secured approval with the FDA for Zeposia (ozanimod) 0.92mg in relapsing forms of multiple sclerosis (RMS), but …


Biogen stock surges following patent victory over Mylan for Tecfidera

February 6, 2020
Sales and Marketing Biogen, Mylan, multiple sclerosis, pharma, tecfidera

Biogen has emerged victorious in a patent dispute with Mylan relating to the latter’s multiple sclerosis therapy Tecfidera – a …


Multiple sclerosis market to be worth $32.9bn in 2028

December 11, 2019
Research and Development Big Pharma, MS, MS treatement, multiple sclerosis, pharma

The multiple sclerosis (MS) market is expected to see a growth in sales, and increase from $19.8 billion in 2018 …


FDA approves first three generic versions of Novartis’ Gilenya for relapsing multiple sclerosis

December 6, 2019
Medical Communications, Sales and Marketing Novartis, generics, gilenya, multiple sclerosis, pharma

The FDA has approved the first three generic versions of Novartis’ sphingosine 1-phosphate receptor modulator Gilenya (fingolimod) to treat adult …


EMA advisory panel recommends Mayzent for secondary progressive multiple sclerosis

November 18, 2019
Sales and Marketing Europe, Mayzent, Novartis, multiple sclerosis, pharma

Novartis has revealed that Mayzent (siponimod) has been recommended by the European Medicines Agency’s (EMA) Committee for Medicinal Products for …

Latest content